IL6R and new-onset refractory status epilepticus: Novel tailored immunotherapies targeting specific cytokines (e.g., interleukin-1 receptor antagonist—anakinra, and interleukin-6 receptor inhibitor—tocilizumab) have been shown to be effective in new-onset refractory status epilepticus (NORSE) and febrile-infection related epilepsy syndrome (FIRES) [70, 71].